Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons
Authors:
Open Access
- 3 April 2017
- journal article
- review article
- Published by Wiley in Parkinson's Disease
- Vol. 2017, 1-13
Abstract
Vascular endothelial growth factor-B (VEGF-B), when initially discovered, was thought to be an angiogenic factor, due to its intimate sequence homology and receptor binding similarity to the prototype angiogenic factor, vascular endothelial growth factor-A (VEGF-A). Studies demonstrated that VEGF-B, unlike VEGF-A, did not play a significant role in angiogenesis or vascular permeability and has become an active area of interest because of its role as a survival factor in pathological processes in a multitude of systems, including the brain. By characterization of important downstream targets of VEGF-B that regulate different cellular processes in the nervous system and cardiovascular system, it may be possible to develop more effective clinical interventions in diseases such as Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and ischemic heart disease, which all share mitochondrial dysfunction as part of the disease. Here we summarize what is currently known about the mechanism of action of VEGF-B in pathological processes. We explore its potential as a homeostatic protective factor that improves mitochondrial function in the setting of cardiovascular and neurological disease, with a specific focus on dopaminergic neurons in Parkinson’s disease.Keywords
This publication has 100 references indexed in Scilit:
- The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's diseaseNeuroscience, 2011
- Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesiaBrain, 2011
- Cardiovascular Disease and mTOR SignalingTrends in Cardiovascular Medicine, 2011
- Neuronal FLT1 receptor and its selective ligand VEGF‐B protect against retrograde degeneration of sensory neuronsThe FASEB Journal, 2011
- PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s DiseaseScience Translational Medicine, 2010
- Oxidative stress: Biomarkers and novel therapeutic pathwaysExperimental Gerontology, 2010
- Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIBActa Neuropathologica, 2008
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- On the Origin of Cancer CellsScience, 1956